Why Gilead’s visceral leishmaniasis collaboration with WHO matters beyond drug donation
Gilead’s WHO pact targets kala-azar access, but diagnostics, treatment delivery and East Africa execution will decide the impact.
Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy
Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.
Gilead’s Trodelvy gains EU regulatory momentum, but the first-line TNBC fight is only beginning
Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.
How Gilead Sciences, Inc. could strengthen its liver disease franchise through Hepcludex commercialization
FDA approval of Hepcludex gives HDV its first U.S. therapy. Find out how this could reshape liver disease treatment and Gilead’s strategy.
Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished
Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.
Why Gilead’s Arcellx acquisition approval could reshape the multiple myeloma CAR-T race
Gilead has cleared regulatory hurdles for Arcellx. Read why the anito-cel takeover could reshape the multiple myeloma CAR-T market.
Why Tubulis gives Gilead more than just another antibody-drug conjugate asset
Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.
Why Gilead’s Arcellx tender extension matters more for cell therapy execution than for deal timing
Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
Why Gilead Sciences’ Arcellx acquisition reshapes the competitive dynamics of BCMA CAR T therapy
Gilead Sciences’ acquisition of Arcellx signals a strategic shift in CAR T therapy control and scale. Find out what it changes for multiple myeloma.